Drugs for malaria: something old, something new, something borrowed by Hobbs, Charlotte & Duffy, Patrick
Drugs for malaria: something old, something new, something
borrowed
Charlotte Hobbs
1 and Patrick Duffy
2*
Addresses:
1NIH/NIAID, Laboratory of Malaria Immunology and Vaccinology, 12735 Twinbrook Parkway, 3W19E, Rockville, MD 20852, USA;
2NIH/NIAID, Laboratory of Malaria Immunology and Vaccinology, Division of Intramural Research, 5640 Fishers Lane, Rm. 1111 Rockville,
MD 20892, USA
*Corresponding author: Patrick Duffy (patrick.duffy@nih.gov)
F1000 Biology Reports 2011, 3:24 (doi:10.3410/B3-24)
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. You may not use this work for commercial purposes.
The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/b/3/24
Abstract
Malaria was estimated to cause 800,000 deaths and 225 million cases worldwide in 2010. Worryingly,
the first-line treatment currently relies on a single drug class called artemisinins, and there are signs
that the parasite is becoming resistant to these drugs. The good news is that new technology has
given us new approaches to drug discovery. New drugs generated this way are probably 10-15 years
away from the clinic. Other antimalarials that may offer hope include those rehabilitated after not
being used for some time, those that act as inhibitors of resistance mechanisms, those that limit
infection while allowing protective immunity to develop, and those which are drugs borrowed from
other disease treatments. All of these offer new hope of turning the tables on malaria. In parallel with
the effort to develop vaccines that interrupt malaria transmission, drugs that target the parasite
during transmission to the mosquito or during its pre-erythrocytic development in the liver, may
allow us to terminate the parasite’s spread.
Introduction
The World Health Organization (WHO) estimated
800,000malariadeathsand225millioncasesworldwide
in 2010 [1], with severe disease concentrated among
youngchildrenandpregnantwomen[2].Geographically,
malaria overlaps with other infectious maladies includ-
ing HIV, which often complicate the illness as well as
treatment options. Worryingly, first-line treatment for
malaria currently relies on a single drug class called
artemisinins, and the existing drug armamentarium is
insufficient to answer the call for malaria eradication.
Under the circumstances, scientists are exploring many
approaches, targeting different stages of the parasite life
cycle, to find agents that will prevent, cure, or eliminate
malaria. These approaches include new drug discovery,
old drug rehabilitation, and drugs borrowed from other
fields for use against malaria.
Malaria parasites: many potential targets, few
effective drugs
Malaria life cycle
Human malaria is transmitted by the bite of female
Anopheles mosquitoes that carry sporozoites (the motile
infective stage of the parasite) in their salivary glands
(Figure 1). Sporozoites inoculated into skin enter blood
vessels and are carried to the liver, where they pass
through Kupffer cells, invade hepatocytes, and multiply
10-thousand-fold over a week to form liver stage mer-
ozoites. Plasmodium vivax and Plasmodium ovale parasites
that invade the liver may develop into a dormant form
called hypnozoite that can cause relapse after months or
years. These stages of infection, called the pre-erythrocytic
(pre-blood) stages, are clinically silent. Liver stage mer-
ozoites released into the blood stream infect individual
host red blood cells to initiate the erythrocytic (blood)
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falciparum malaria can rapidly progress to death. Along
with the disease-causing asexual blood stage parasites,
sexual stages known as gametocytes also emerge during
blood stage development [3]. In Plasmodium falciparum,
gametocytes appear several days after asexual parasites,
whereas P. vivax gametocytes can appear at the same time
or even before asexual forms in the blood [4].
Malaria drug history
Quinine and its derivatives
The first pharmaceutical used to treat malaria, quinine,
was derived from the tree bark of Cinchona calisaya [5].
Quinine synthesis was first attempted in 1856 by William
HenryPerkins,butsynthesiswasnotsuccessfuluntil1944.
Although he failed with quinine, Perkins did succeed
in synthesizing “mauve,” the first textile dye, thereby
launching the synthetic textile dye industry in Germany.
Microbiologists adopted these dyes to stain microorgan-
isms, and methylene blue was first found to stain malaria
parasites by Paul Erlich. Erlich hypothesized that methy-
lene blue might therefore kill malaria parasites, and toge-
ther with Paul Guttman successfully treated two malaria
patients with this agent [6]. Indeed, methylene blue was
the predecessor to both the 4-aminoquinolones and the
8-aminoquinolones. Chloroquine is perhaps the most
important of the 4-aminoquinolones, and other related
compounds include the aminophenols amodiaquine and
pyronaridine, and the dimeric 4-aminoquinoline, piper-
aquine. The 8-aminoquinolones including the prototype
pamaquine (which was too toxic and so not used for
long), primaquine (still in use today as the only licensed
drug effective against the dormant liver form, the
hypnozoite), and tafenoquine (a drug which is under-
going clinical trials applied as an anti-hypnozoite form
treatment). Other derivatives of quinine include the
arylamino alcohols mefloquine, halofantrine, and lume-
fantrine [7]. Parenteral quinine remains an option for the
treatment of severe malaria, although parenteral artesu-
nate has shown superior efficacy in recent trials [8]. Both
chloroquine and primaquine are synthetic derivatives of
quinine, and their development in the mid-20
th century
was largely driven by the need to treat soldiers during the
world wars [9,10]. Each of these drugs, still in use today,
probably act by interfering with the parasite’s ability to
eliminate the toxic by-products of hemoglobin digestion.
Antifolates
Other drugs have specific enzyme targets in the parasite,
such as the antifolates (e.g. sulfadoxine-pyrimethamine),
which inhibit the parasite’s essential ability to synthesize
tetrahydrofolate used for methylation reactions [4]. Anti-
folatesweredemonstratedtobeeffectiveagainstmalariaas
early as the 1930s, and sulfonamide components with
better pharmacokinetic profiles and partner drugs were
developed overthe 1940s and 50s,but antifolates were not
generally used for antimalarial treatment until much later
owing to the availability of highly effective quinine
Figure 1. Life cycle of the malaria parasite
Sporozoitesinoculatedintoskinenterbloodvesselsandarecarriedtotheliver,
where they multiply to form liver stage merozoites. Liver stage merozoites
released into the blood stream infect individual host red blood cells to initiate
the erythrocytic (blood) stages. Along with the disease-causing asexual blood
stage parasites, sexual stages, known as gametocytes, also emerge during blood
stage development and serve to transmit the infection to mosquitoes that suck
the blood of infected humans. See [69] for a more in-depth summary.
Abbreviations: RBC, red blood cell. Reproduced from Figure 1, panel B from
http://www.sciencedirect.com/science/article/pii/S1471492211000353. Figure
reproduced with kind permission of authors Robert J. Schwenk and Thomas
L. Richie and Trends in Parasitology (copyright license obtained) [69].
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able in 1971 as second-line therapy for malaria, with
resistance developing not long thereafter [11]. Indeed,
resistance to antifolate drugs, for which there is a specific
enzyme target, evolved more rapidly than resistance to
chloroquine [4].
Artemisinin combination therapy
Unfortunately, the malaria parasite has developed
resistance to all the above drugs in different parts of the
world. In response to this, WHO recommended artemi-
sinin combination therapy in recent years.
Artemisinin, a derivative of sweet wormwood, Artemisia
annua, is a potent drug that rapidly reduces blood stage
parasites, allowing prompt resolution of illness, and
was initially developed in 1972 by the Chinese during
the Vietnam War. Ho Chi Minh personally asked Mao
Zedong for assistance with antimalarials, as North
Vietnamese soldiers were dying from malaria at a higher
rate than from armed conflicts [12]. Artemisinin combi-
nation therapy represented a shift away from mono-
therapy for malaria, which was common previously.
Since artemisinin and its derivatives have very short half-
lives, a second drug with longer half-life is used in
combination to complete the clearance of parasitemia,
and the combination of drugs has the additional benefit
to forestall the development of resistance. In Cambodia,
parasite sensitivity to artemisinin may already be
decreasing [13]. In response to this alarming pattern,
WHO has formulated a Global Plan for Artemisinin
Resistance Containment (GPARC) to address the
need for specific and immediate actions to limit spread
[14]. Several candidate genes have been proposed to be
important in the development of artemisinin resistance
[15], but this remains a key ongoing area of research.
Complexities of treatment: stages and species
Species
Five species of the malaria parasite, Plasmodium spp.,
infect humans, with P. falciparum causing the most
mortality worldwide and P. vivax causing significant
morbidity.P.vivax,amajorcontributortomalaria-related
morbidity, is more common in areas of lower transmis-
sion intensity, and therefore relapses originating from
P. vivax dormant form hypnozoites in the liver may
be an important contributor to disease incidence [16].
P. ovale and Plasmodium malariae are agents of the so-
called “benign malarias,” and like P.vivax, P. ovale can
cause relapsing infections. P. malariae can persist as a
blood stage parasite at very low levels and flare up
decades after initial infection. Morphologically, P. malar-
iae has been confused on bloodsmear with the recently
identified zoonosis, Plasmodium knowlesi, which has a
shorter life-cycle of replication than any of the other
human malarias, and can cause rapidly progressive and
fatal disease if not treated promptly [17].
Stages
Currently available antimalarials mainly target the
symptomatic asexual blood stages, in order to be useful
for treatment as earlier stages of infection are clinically
silent. In keeping with this, the growth inhibition assay
for asexual blood stage P. falciparum is the primary
screening tool used for candidate antimalarials [4, 18-
22]. Consequently, although drugs against the dormant
hypnozoites and transmissible gametocytes are needed
for elimination programs, such drugs are difficult to
identify and test, and the drugs used against asexual
stages are generally ineffective for these other stages [5].
The only currently available drug which can kill the
dormant form hypnozoite and the gametocyte is
primaquine, but primaquine cannot be used in patients
with glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency or in pregnant women.
Another problem is that lack of standardized assays
which could be used to test drugs against dormant form
hypnozoites [23] limits drug development for this
indication. Rodent models allow screening of blood
stage drugs, but rodent parasites do not form hypno-
zoites [24]. The relapsing Plasmodium cynomolgi model in
non-human primates was used in the development of
primaquine, but primate models are expensive, low
throughput, and not available in many malaria research
centers. In vitro models of liver stage infection also have
many limitations, including difficulty obtaining spor-
ozoites and low infection rates. Whether cultured hepa-
tocytes retain their in vivo architecture, metabolism, or
receptors is an additional concern [25]. On top of this,
dormant hypnozoite forms are difficult to distinguish
from the early liver exoerythrocytic forms. Despite these
obstacles, progress is being made in the development of
liver stage hypnozoite assays, albeit none of these appear
amenable to high throughput capability that would
support clinical drug development [26-28].
Identification of drugs with anti-gametocyte and
transmission-blocking effects would aid in eradication
efforts. Although artemisinin and its derivatives have
been shown to reduce carriage of gametocytes, they do
not prevent transmission of mature gametocytes already
present at the time of treatment [32-34]. Indeed, the only
drug officially recommended by WHO to eliminate
gametocytes is primaquine for P. falciparum [8], and
encouragingly primaquine has been recently shown to
reduce transmission when added to an artemisinin com-
bination therapy in an open-label, randomized trial [32].
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sexual stage parasites and parasite transmission to
mosquitoes are available in select centers [29,31].
Overcoming resistance
Drug resistant parasites typically develop when drugs are
at subtherapeutic levels, and therefore the short half-life
of artemisinins may protect this class of drugs [19,35]. In
addition, pairing the artemisinin derivative with other
antimalarial drugs with dissimilar mechanisms of action
will delay the emergence of drug resistant parasites.
However, because outpatient therapy now relies on this
single class of antimalarials, the artemisinins, all of the
artemisinin combination therapies will become vulner-
able to failure once fully artemisinin-resistant parasites
develop and spread. It is not clear whether the synthetic
artemisinin analogues currently under early stage devel-
opment will still be useful if and when this happens.
Something new: new drug candidates
The good news on the antimalarial development front is
that scientific and technological advances will allow for
more rapid identification of effective therapy and new
targets.
The sequencing of various Plasmodium genomes [36, 37]
has accelerated target identification and expression analy-
sis. Orthologues (genes that evolved from a common
ancestral gene in different species that generally retain the
samefunction)fortargetsofinterestcanbeeasilyidentified
and small molecules against these targets tested in vivo
(animal models) or in vitro. High throughput screening
in vitro can identify active molecules that can be further
optimized for preclinical testing [38]. The molecular-based
search for targets is referred to as the “rational design
approach.” This approach has not yet delivered a product,
in part because the time from molecular target identifi-
cation to clinic testing is great. One problem with this
approach is that it favors identification of drugs with one
rather than multiple targets, making these more likely to
induce parasite resistance.
Others have advocated the “whole parasite screening”
approach: molecules are selected from available chemi-
cal data, and hits (molecules) are identified through high
throughput screening with whole parasites. Molecular
targets are then established by generating mutant
parasites that are resistant to the active or “hit” molecule.
If a particular antimalarial has many targets, it has a
lower chance of encountering resistant parasites. This
method recently resulted in the identification of a new
candidate antimalarial, the spiroindolone NITD609, by
Rottman et al. [39], which has been shown to be safe for
testing in humans [40].
Mass screening of chemical libraries has yielded a wealth
of potential antimalarial compounds, and many are
active at sub-micromolar concentrations with minimal
toxicity to human cell lines. Screening assays in 1536-
well formats exist for asexual blood stage P. falciparum,
and assays are under development for the dormant liver
hypnozoite and transmission stages. In a screen of 2816
registered or approved compounds, 32 compounds were
recently found to be active against 45 parasite lines
sourced from around the world with IC50 values ≤ 1 mM,
including 10 compounds not previously known to have
anti-malarial activity. Genome-wide association and
linkage analysis then identified compounds that had
similar or distinct mechanisms of action, which might
predict cross-resistance and therefore guide combination
therapy [41].
To manage such large quantities of data being generated
by different groups, a centralized database of high
throughput screening results to “facilitate assimilation,
integration, and mining of data” has been started by the
WHO, the United Nations, and the World Bank-
sponsored Tropical Disease Research group. Also,
public-private partnerships and non-profit organiza-
tions, such as Medicines for Malaria Venture, Drugs for
Neglected Diseases Initiative (DNDi), and African Net-
work for Drugs and Diagnostics Innovation (ANDI),
have been developed with the idea of maximizing
collaborations and developing new therapies [4].
The current pipeline
Medicines for Malaria Venture, a non-profit group that
supports scientists and companies to develop new
antimalarials, highlights a number of compounds
considered leads in optimization, as well as antimalarials
in the pipeline (preclinical through Phase IV develop-
ment) on their website, (http://www.mmv.org/research-
development?gclid=CJPY–7e96oCFWUTNAod80I-Pg).
Many of these compounds are newly identified or novel
in their application to antimalarial therapy.
The initial approach to tackling drug resistance was to
develop drugs based on structures of existing antimalar-
ials,andthishasbeenaprofitableendeavor.Antimalarials
developed based on chloroquine include lumefantrine,
piperaquine and pyronaridine developed in China, each
of which are now components of artemisinin combina-
tion therapys in use or in advanced trial stages. In the
United States, other chloroquine-like antimalarials
include amodiaquine (also used in artemisinin combina-
tion therapy), mefloquine, and halofantrine, although the
last of these is not widely used clinically today [4]. Drugs
with indirect or direct disruption of pyrimidine meta-
bolism (e.g. pyrimethamine, sulfonamides, atovaquone)
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another aspect ofthe pyrimidinepathway:dihydroorotate
dehydrogenase[42].Someoftheleadcandidatesbasedon
already successful antimalarials [40] are highlighted
below:
4-Aminoquinolone derivatives
Pyronaridine, a chloroquine relative, is being used in
combination with artesunate as a promising new
artemisinin-based combination therapy. Pyronaridine-
artesunate has been studied in Phase II and Phase III
clinical trials, and has been shown to be effective against
uncomplicatedP.falciparumandbloodstageP.vivax[43].
As increasingly chloroquine-resistant strains of P. vivax
emerge, and as the need to treat P. falciparum and P. vivax
co-infection expands in certain areas, such a regimen
is welcome. Pyronaridine-artesunate is available as
Pyramax® tablets and pediatric granule formulations,
and manufacture of this compound is being undertaken
by Shin Poong Pharmaceuticals [40].
8-Aminoquinolone derivatives
Tafenoquine is a lead candidate drug aimed at a radical
cure of P. vivax (i.e. elimination of dormant stage
hypnozoites), and is being studied in a Phase II/III
tafenoquine/chloroquine combination study this year
[40]. A fixed dose artemisinin combination therapy,
artesunate-amodiaquine (Coarsucam/ASAQ, Winthrop)
has been approved by WHO and developed by Sanofi-
Aventis and the DNDi, and is undergoing Phase IV field
assessment [40].
Artemisinin derivatives
The endoperoxide feature of artemisinins, which confers
antimalarial activity, is shared by ozonide OZ439, a
synthetic endoperoxide. OZ439 carries the hope of
providing a single dose oral cure in humans when used
in combination. OZ439 is a rapidly acting agent against
asexual stage parasites, and will likely be developed for
use in combination with a partner drug with a longer
half-life than its own. Studies are underway to identify
such a partner. This drug is currently undergoing Phase
IIa trials. [44]
Caveats
For all of these drugs, the caveats regarding antimalarial
resistance and ease of dosing and administration remain.
Pharmacokinetic trials in adults, once done, must be
followed by appropriate pharmacokinetic studies in
children, as it is well known that certain antimalarials
(such as piperaquine and sulfadoxine-pyrimethamine)
have differing pharmacokinetics in children compared
with adults, which will modify their efficacy [45]. Drug
efficacy is also influenced by the degree of pre-existing
antimalarial immunity, acquired as children get older
and are exposed to malaria over and over again [46].
Thus, drug efficacy must be evaluated in children and
must take into account these additional factors.
Something old: novel approaches with existing
antimalarials
Drug cycling
Re-introductionofdrugsafteraperiodofnon-usehasbeen
considered as a strategy to combat malaria. In Malawi,
which halted chloroquine use in 1993 due to resistance,
chloroquine was demonstrated to have 99% clinical
efficacy a decade later, presumably due to the re-expansion
of susceptible parasites [47, 48]. However, in time it is
likely that the re-introduction of drug pressure will likely
result in re-emergence of chloroquine-resistant parasites.
One way to delay this would be to pair the re-cycled drug
with another drug. Combinations of quinine derivatives
with antimicrobials have shown synergy, for example
chloroquine/azithromycin (which has the advantage that
it is safe for children and pregnant women). Clinical
studies are underway to assess this combination for use
as intermittent preventative treatment, (administration at
defined intervals regardless of whether the patient has
malaria parasites in the blood, is recommended for
pregnant women and infants designed to provide prophy-
laxis against malaria [40, 49]).
Getting round resistance
Preventing resistance in the first place is the major focus of
antimalarial drug development today. Artemisinin combi-
nation therapies represent a change in antimalarial therapy
paradigms since most drugs had been given as a mono-
therapy in the past. Indeed the use of artesunate mono-
therapy might have contributed to the development of
artemisinin-resistant parasites recently reported in Western
Cambodia [13]. In the present and future, combination
therapy will enhance efficacy of individual antimalarials
and reduce the likelihood of developing resistance.
In addition, agents that reverse resistance to existing anti-
malarials might extend the useful lifetime of old drugs.
Many compounds, including various calcium channel
blockers and chlorpheniramine, and even primaquine,
as examples, have been shown to reverse chloroquine
resistance. However, this approach is not completely
straightforward. Drug metabolism, drug levels required to
achieve the therapeutic effect, and the lack of clinical
researchinthisarea,allrepresentobstaclestotranslatethis
approach into practice [50]. Interestingly, parasites that
develop high-grade resistance mutations to antifolates,
such as pyrimethamine, might actually be rendered more
sensitive to certain novel inhibitors of antifolate metabo-
lism, such as WR99210 [51].
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A novel area of malaria research involves examining the
unforeseen benefits of treatment in the development of
malaria-specific immunity. In experimental human
infection models, complete protection against infection
has been induced when patients are repeatedly exposed
to infection while taking antimalarials [52]. This form of
immunity was found to endure for 2 years or more in
some individuals [53], making this an exciting potential
approach to malaria prevention. However, testing has
thus far been limited to challenge with homologous
parasites (the parasite used to vaccinate is the same as
that used to challenge volunteers), and therefore future
studies will need to examine the degree of immunity
induced against heterologous or naturally transmitted
parasites.
Something borrowed: novel uses of other
anti-infectives
Drugs used in the management of HIV infection
HIV protease inhibitors have been shown to have direct
anti-parasiteeffects.Giventhegeographicoverlapbetween
HIV and malaria in sub-Saharan Africa, and evidence that
malaria and HIV exert a co-pathogenic effect [2, 54-59],
any coincident effect of HIV medications on the malaria
parasite would have an obvious benefit. HIV protease
inhibitors directly interfere with Plasmodium growth
in vitro, in vivo,a n dex vivo [7, 60-64]. Clinical studies of
thiseffectare urgentlyneeded,especiallysince WHO,with
few exceptions, does not recommend HIV protease
inhibitors for first line antiretroviral regimens.
In addition, HIV protease inhibitors may have
chloroquine-resistance reversing properties, according
to a patent filed in 2005 [50]. Saquinavir and ritonavir
behave synergistically with chloroquine and mefloquine,
against chloroquine sensitive and resistant strains of
P. falciparum [65]. Various HIV protease inhibitors have
also been shown to act synergistically against Plasmodium
chabaudi in vivo. [66,67] Synergy might result from HIV
protease inhibitors reducing levels of specific enzymes
and products (GSH and glutathione) used by the parasite
to detoxify by-products of hemoglobin digestion [68].
Conclusions
The parasite’s ability to evolve and adapt to every drug
introduced thus far mandates research to identify new
targets for antimalarial therapy. New technologies and
high throughput approaches are identifying a burgeon-
ing number of drug candidates and novel drug classes
with antimalarial activity, however the sobering reality is
that only a limited number of antimalarial drugs have
emerged from the development pipeline to enter clinical
practice over the past century. The Medicines for Malaria
Venture estimates 10-15 years between drug screening
and ultimate registration, and thus many of the pre-
clinical antimalarial candidates discussed in this article
will not be seen in the clinic in the immediate future.
In addition, the call for malaria elimination and
eradication is spurring the development of anti-malarials
that target the parasite in life cycle stages that were largely
ignored by drug developers in the past. In parallel with
the effort to develop vaccines that interrupt malaria
transmission, the drugs needed to contribute to elimi-
nation or eradication will target the parasite during tran-
smission to the mosquito or during its pre-erythrocytic
development in the liver, in order to terminate the
parasite’s spread. All this is a tall order for a drug pipeline
that has been historically slow, and hence the need to
consider all potential avenues—new, old, or borrowed—
to revive the malaria armamentarium.
Abbreviations
DNDi, Drugs for Neglected Diseases Initiative; WHO,
World Health Organization.
Competing interests
The authors declare that they have no competing
interests
References
1. World Malaria Report. World Health Organization (WHO);
2010. [http://www.who.int/malaria/world_malaria_report_2010/
worldmalariareport2010.pdf]
2. Slutsker L, Marston BJ: HIV and malaria: interactions and
implications. Curr Opin Infect Dis 2007, 20:3-10.
3. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL,
Collins FH, Duffy PE: Malaria: progress, perils, and prospects
for eradication. J Clin Invest 2008, 118:1266-76.
4. Wells TN, Alonso PL, Gutteridge WE: New medicines to improve
control and contribute to the eradication of malaria. Nat Rev
Drug Discov 2009, 8:879-91.
5. Alonso PL, Bassat Q, Binka F, Brewer T, Chandra R, Culpepper J,
Dinglasan R, Duncan K, Duparc S, Fukuda M, Laxminarayan R,
M a c A r t h u rJ R ,M a g i l lA ,M a r z e t t aC ,M i l m a nJ ,M u t a b i n g w aT ,N o s t e nF ,
Nwaka S, Nyunt M, Ohrt C, Plowe CV, Pottage J, Price R, Ringwald P,
Serazin A, Shanks D, Sinden R, Tanner M, Vial H, Ward SA: A research
agenda for malaria eradication: drugs. PLoSMed 2011, 8:e1000402.
6. Schlitzer M: Malaria chemotherapeutics part I: History of
antimalarial drug development, currently used therapeutics,
and drugs in clinical development. Chem Med Chem 2007,
2:944-86.
7. Martins TM, Domingos A, Berry C, Wyatt DM: The activity and
inhibition of the food vacuole plasmepsin from the rodent
malaria parasite Plasmodium chabaudi. Acta Trop 2006,
97:212-8.
8. Guidelines for the Treatment of Malaria. World Health
Organization (WHO); 2009. [http://whqlibdoc.who.int/publications/
2010/9789241547925_eng.pdf]
9. Baird JK: Resurgent malaria at the millennium: control
strategies in crisis. Drugs 2000, 59:719-43.
10. Baird JK, Hoffman SL: Primaquine therapy for malaria. Clin Infect
Dis 2004, 39:1336-45.
11. Baird JK: Effectiveness of antimalarial drugs. N Engl J Med 2005,
352:1565-77.
Page 6 of 9
(page number not for citation purposes)
F1000 Biology Reports 2011, 3:24 http://f1000.com/reports/b/3/241 2 . E f f e r t hT ,R o m e r oM R ,W o l fD G ,S t a m m i n g e rT ,M a r i nJ J ,
Marschall M: The antiviral activities of artemisinin and
artesunate. Clin Infect Dis 2008, 47:804-11.
13. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM,
Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M,
Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P,
Day NP, Lindegardh N, Socheat D, White NJ: Artemisinin
resistance in Plasmodium falciparum malaria. N Engl J Med
2009, 361:455-67.
F1000 Factor 10
Evaluated by Patrick Duffy 20 Oct 2011
14. Global plan for Artemisinin Resistance Containment. World
Health Organization (WHO); 2011. [http://www.who.int/malaria/
publications/atoz/9789241500838/en/index.html]
15. Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S,
Das D, Phyo AP, Lwin KM, Pukrittayakamee S, Lee SJ, Saisung S,
Koecharoen K, Nguon C, Day NP, Socheat D, White NJ: Exploring
the contribution of candidate genes to artemisinin resistance
in Plasmodium falciparum. Antimicrob Agents Chemother 2010,
54:2886-92.
16. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP,
Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR,
Baird JK, Snow RW, Hay SI: The international limits and
population at risk of Plasmodium vivax transmission in
2009. PLoS Negl Trop Dis 2010, 4:e774.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
17. Lee KS, Divis PC, Zakaria SK, Matusop A, Julin RA, Conway DJ, Cox-
Singh J, Singh B: Plasmodium knowlesi: reservoir hosts and
tracking the emergence in humans and macaques. PLoS Pathog
2011, 7:e1002015.
18. Baniecki ML, Wirth DF, Clardy J: High-throughput Plasmodium
falciparum growth assay for malaria drug discovery. Antimicrob
Agents Chemother 2007, 51:716-23.
F1000 Factor 10
Evaluatedby DavidNewman05 Mar2007, PatrickDuffy20 Oct2011
19. Burrows JN, Chibale K, Wells TN: The state of the art in anti-
malarial drug discovery and development. Curr Top Med Chem
2011, 11:1226-54.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
20. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL,
Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE,
Cardon LR, Garcia-Bustos JF: Thousands of chemical starting
points for antimalarial lead identification. Nature 2010,
465:305-10.
F1000 Factor 14
Evaluated by Jeffrey Aubé 01 Jun 2010, David Triggle 01 Jun 2010,
Patrick Duffy 20 Oct 2011
21. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH,
Smithson DC, Connelly M, Clark J, Zhu F, Jiménez-Díaz MB,
Martinez MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El
Mazouni F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-
BarturenI,FerrerS,RosenthalPJ,DerisiJL,SullivanDJ,LazoJS,RoosDS,
Riscoe MK, Phillips MA, Rathod PK, Van Voorhis WC, Avery VM,
Guy RK: Chemical genetics of Plasmodium falciparum. Nature
2010, 465:311-5.
F1000 Factor 10
Evaluated by Jeffrey Aubé 01 Jun 2010, Patrick Duffy 20 Oct 2011
22. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K,
Nagle A, Adrian F, Matzen JT, Anderson P, Nam TG, Gray NS,
Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG,
Zhou Y, Winzeler EA: In silico activity profiling reveals the
mechanism of action of antimalarials discovered in a high-
throughput screen. Proc Natl Acad Sci U S A 2008, 105:9059-64.
F1000 Factor 14
Evaluated by Paul Roepe 03 Jul 2008, Thomas Kodadek 04 Jul 2008,
Kim Lewis 07 Jul 2008, Patrick Duffy 20 Oct 2011
23. Wells TN, Burrows JN, Baird JK: Targeting the hypnozoite
reservoir of Plasmodium vivax: the hidden obstacle to
malaria elimination. Trends Parasitol 2010, 26:145-51.
24. Langhorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D,
Mota MM, Pasini E, Renia L, Riley E, Stins M, Duffy P: The relevance
of non-human primate and rodent malaria models for
humans. Malar J 2011, 10:23.
25. Silvie O, Rubinstein E, Franetich JF, Prenant M, Belnoue E, Renia L,
Hannoun L, Eling W, Levy S, Boucheix C, Mazier D: Hepatocyte
CD81 is required for Plasmodium falciparum and Plasmo-
dium yoelii sporozoite infectivity. Nat Med 2003, 9:93-6.
F1000 Factor 9
EvaluatedbyDominiqueSoldati14Jan2003,PatrickDuffy20Oct2011
26. Chattopadhyay R, Velmurugan S, Chakiath C, Andrews Donkor L,
Milhous W, Barnwell JW, Collins WE, Hoffman SL: Establishment of
an in vitro assay for assessing the effects of drugs on the liver
stages of Plasmodium vivax malaria. PLoS One 2010, 5:e14275.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
27. Dembele L, Gego A, Zeeman AM, Franetich JF, Silvie O, Rametti A, Le
Grand R, Dereuddre-Bosquet N, Sauerwein R, van Gemert GJ,
Vaillant JC, Thomas AW, Snounou G, Kocken CH, Mazier D: Towards
an in vitro model of Plasmodium hypnozoites suitable for drug
discovery. PLoS One 2011, 6:e18162.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
28. Sattabongkot J, Yimamnuaychoke N, Leelaudomlipi S, Rasameesoraj M,
Jenwithisuk R, Coleman RE, Udomsangpetch R, Cui L, Brewer TG:
Establishment of a human hepatocyte line that supports in
vitro development of the exo-erythrocytic stages of the
malaria parasites Plasmodium falciparum and P. vivax.
Am J Trop Med Hyg 2006, 74:708-15.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
29. Buchholz K, Burke TA, Williamson KC, Wiegand RC, Wirth DF,
Marti M: A high-throughput screen targeting malaria trans-
mission stages opens new avenues for drug development.
J Infect Dis 2011, 203:1445-53.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
30. Tanaka TQ, Williamson KC: A malaria gametocytocidal assay
using oxidoreduction indicator, alamarBlue. Mol Biochem
Parasitol 2011, 177:160-3.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
31. Wells TN, Poll EM: When is enough enough? The need for a
robust pipeline of high-quality antimalarials. Discov Med 2010,
9:389-98.
32. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL,
Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ:
Effectiveness of five artemisinin combination regimens with
or without primaquine in uncomplicated falciparum malaria:
an open-label randomised trial. Lancet Infect Dis 2010, 10:673-81.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
33. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A,
Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA,
Sauerwein RW: Moderate effect of artemisinin-based
Page 7 of 9
(page number not for citation purposes)
F1000 Biology Reports 2011, 3:24 http://f1000.com/reports/b/3/24combination therapy on transmission of Plasmodium falci-
parum. J Infect Dis 2006, 193:1151-9.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
34. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L,
Chongsuphajaisiddhi T, White NJ: Effects of artemisinin deriva-
tives on malaria transmissibility. Lancet 1996, 347:1654-8.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
35. White N: Antimalarial drug resistance and combination
chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999,
354:739-49.
36. CarltonJM,AdamsJH,SilvaJC,BidwellSL,LorenziH,CalerE,CrabtreeJ,
Angiuoli SV, Merino EF, Amedeo P, Cheng Q, Coulson RM, Crabb BS,
Del Portillo HA, Essien K, Feldblyum TV, Fernandez-Becerra C,
Gilson PR, Gueye AH, Guo X, Kang'a S, Kooij TW, Korsinczky M,
Meyer EV, Nene V, Paulsen I, White O, Ralph SA, Ren Q, Sargeant TJ,
Salzberg SL, Stoeckert CJ, Sullivan SA, Yamamoto MM, Hoffman SL,
Wortman JR,Gardner MJ,GalinskiMR,Barnwell JW, Fraser-LiggettCM:
Comparative genomics of the neglected human malaria
parasite Plasmodium vivax. Nature 2008, 455:757-63.
F1000 Factor 10
Evaluated by Frank Seeber 21 Oct 2008, Patrick Duffy 20 Oct 2011
37. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW,
Carlton JM, Pain A, Nelson KE, Bowman S, Bowman S, Paulsen IT,
James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS,
Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J,
Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH,
Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM,
Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL,
Newbold C, Davis RW, Fraser CM, Barrell B: Genome sequence of
the human malaria parasite Plasmodium falciparum. Nature
2002, 419:498-511.
F1000 Factor 10
Evaluated by Carol Sibley 16 Oct 2002, Patrick Duffy 20 Oct 2011
38. Wells TN: Microbiology. Is the tide turning for new malaria
medicines? Science 2010, 329:1153-4.
39. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B,
Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR,
González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R,
Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V,
Keller TH, Fidock DA, Winzeler EA, Diagana TT: Spiroindolones, a
potent compound class for the treatment of malaria. Science
2010, 329:1175-80.
F1000 Factor 13
Evaluated by Matthew Bogyo 13 Sep 2010, Karin Romisch 14 Oct
2010, Dominique Soldati 02 Dec 2010, David Triggle 09 Dec 2010,
Patrick Duffy 20 Oct 2011
40. Medicines for Malaria Venture. [http://www.mmv.org/]
41. Yuan J, Cheng KC, Johnson RL, Huang R, Pattaradilokrat S, Liu A,
Guha R, Fidock DA, Inglese J, Wellems TE, Austin CP, Su XZ:
Chemical genomic profiling for antimalarial therapies,
response signatures, and molecular targets. Science 2011,
333:724-9.
F1000 Factor 13
Evaluated by Marilyn Parsons 02 Sep 2011, David Triggle 20 Sep
2011, Patrick Duffy 20 Oct 2011
42. PhillipsMA, Rathod PK: Plasmodium dihydroorotate dehydrogen-
ase: a promising target for novel anti-malarial chemotherapy.
Infect Disord Drug Targets 2010, 10:226-39.
43. Kurth F, Belard S, Basra A, Ramharter M: Pyronaridine: a new ‘old’
drug on the verge of entering the antimalarial armamentar-
ium. Expert Rev Anti Infect Ther 2011, 9:393-6.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
44. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M,
Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y,
MatileH,MaurerM,MorizziJ,NguyenT,PapastogiannidisP, ScheurerC,
Shackleford DM, Sriraghavan K, Stingelin L, Tang Y,Urwyler H, Wang X,
WhiteKL,WittlinS,ZhouL,VennerstromJL:Syntheticozonidedrug
candidate OZ439 offers new hope for a single-dose cure of
uncomplicated malaria. Proc Natl Acad Sci U S A 2011, 108:4400-5.
F1000 Factor 10
Evaluated by Wesley Van Voorhis 14 Jul 2011, Patrick Duffy
20 Oct 2011
45. Nosten FH: Pyronaridine-artesunate for uncomplicated falci-
parum malaria. Lancet 2010, 375:1413-4.
46. Rogerson SJ, Wijesinghe RS, Meshnick SR: Host immunity as a
determinant of treatment outcome in Plasmodium falci-
parum malaria. Lancet Infect Dis 2010, 10:51-9.
47. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE,
Plowe CV: Return of chloroquine-susceptible falciparum
malaria in Malawi was a reexpansion of diverse susceptible
parasites. J Infect Dis 2010, 202:801-8.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
48. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK,
Takala SL, Taylor TE, Plowe CV: Return of chloroquine
antimalarial efficacy in Malawi. N Engl J Med 2006, 355:1959-66.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
49. ChicoRM, Pittrof R,GreenwoodB, Chandramohan D:Azithromycin-
chloroquine and the intermittent preventive treatment of
malaria in pregnancy. Malar J 2008, 7:255.
50. Egan TJ, Kaschula CH: Strategies to reverse drug resistance in
malaria. Curr Opin Infect Dis 2007, 20:598-604.
51. Hastings MD, Sibley CH: Pyrimethamine and WR99210 exert
opposing selection on dihydrofolate reductase from Plasmo-
dium vivax. Proc Natl Acad Sci U S A 2002, 99:13137-41.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
52. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van
Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T,
Spaarman L, de Mast Q, Roeffen W, Snounou G, Rénia L, van der
Ven A, Hermsen CC, Sauerwein R: Protection against a malaria
challenge by sporozoite inoculation. N Engl J Med 2009,
361:468-77.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
53. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN,
Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-
Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW:
Long-term protection against malaria after experimental
sporozoite inoculation: an open-label follow-up study. Lancet
2011, 377:1770-6.
54. Abu-Raddad LJ, Patnaik P, Kublin JG: Dual infection with HIV and
malaria fuels the spread of both diseases in sub-Saharan
Africa. Science 2006, 314:1603-6.
F1000 Factor 6
Evaluated by Gabriele Sorci 03 Jan 2007
55. Korenromp EL, Williams BG, de Vlas SJ, Gouws E, Gilks CF, Ghys PD,
Nahlen BL: Malaria attributable to the HIV-1 epidemic, sub-
Saharan Africa. Emerg Infect Dis 2005, 11:1410-9.
56. KublinJG,SteketeeRW:HIVinfectionandmalaria–understanding
the interactions. JI n f e c tD i s2006, 193:1-3.
57. Laufer MK, van Oosterhout JJ, Thesing PC, Dzinjalamala FK, Hsi T,
Beraho L, Graham SM, Taylor TE, Plowe CV: Malaria treatment
efficacy among people living with HIV: the role of host and
parasite factors. Am J Trop Med Hyg 2007, 77:627-32.
Page 8 of 9
(page number not for citation purposes)
F1000 Biology Reports 2011, 3:24 http://f1000.com/reports/b/3/2458. Van Geertruyden JP, Menten J, Colebunders R, Korenromp E,
D’Alessandro U: The impact of HIV-1 on the malaria parasite
biomass in adults in sub-Saharan Africa contributes to the
emergence of antimalarial drug resistance. Malar J 2008, 7:134.
59. Laufer MK, Plowe CV: The Interaction between HIV and
malaria in Africa. Curr Infect Dis Rep 2007, 9:47-54.
60. Andrews KT, Fairlie DP, Madala PK, Ray J, Wyatt DM, Hilton PM,
Melville LA, Beattie L, Gardiner DL, Reid RC, Stoermer MJ, Skinner-
Adams T, Berry C, McCarthy JS: Potencies of human immunode-
ficiency virus protease inhibitors in vitro against Plasmodium
falciparum and in vivo against murine malaria. Antimicrob Agents
Chemother 2006, 50:639-48.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
61. Hobbs CV, Voza T, Coppi A, Kirmse B, Marsh K, Borkowsky W,
Sinnis P: HIV protease inhibitors inhibit the development of
preerythrocytic-stage plasmodium parasites. J Infect Dis 2009,
199:134-41.
62. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, Skinner-Adams TS,
Nosten F, Gardiner DL, Boonma P, Piera KA, Andrews KT,
Machunter B, McCarthy JS, Anstey NM, Price RN, Russell B:
Stronger activity of human immunodeficiency virus type 1
protease inhibitors against clinical isolates of Plasmodium
vivax than against those of P. falciparum. Antimicrob Agents
Chemother 2008, 52:2435-41.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
63. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ:
Antimalarial activity of human immunodeficiency virus
type 1 protease inhibitors. Antimicrob Agents Chemother 2005,
49:2983-5.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
64. Redmond AM, Skinner-Adams T, Andrews KT, Gardiner DL, Ray J,
Kelly M, McCarthy JS: Antimalarial activity of sera from subjects
taking HIV protease inhibitors. AIDS 2007, 21:763-5.
F1000 Factor 8
Evaluated by Patrick Duffy 20 Oct 2011
65. Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL:
Synergistic interactions of the antiretroviral protease inhibi-
tors saquinavir and ritonavir with chloroquine and meflo-
quine against Plasmodium falciparum in vitro. Antimicrob Agents
Chemother 2007, 51:759-62.
66. He Z, Qin L, Chen L, Peng N, You J, Chen X: Synergy of human
immunodeficiency virus protease inhibitors with chloroquine
against Plasmodium falciparum in vitro and Plasmodium
chabaudi in vivo. Antimicrob Agents Chemother 2008, 52:2653-6.
67. Li X, He Z, Chen L, Li Y, Li Q, Zhao S, Tao Z, Hu W, Qin L, Chen X:
Synergy of the antiretroviral protease inhibitor indinavir and
chloroquine against malaria parasites in vitro and in vivo.
Parasitol Res 2011, [Epub ahead of print].
68. He Z, Chen L, You J, Qin L, Chen X: Antiretroviral protease
inhibitors potentiate chloroquine antimalarial activity in
malaria parasites by regulating intracellular glutathione
metabolism. Exp Parasitol 2009, 123:122-7.
F1000 Factor 6
Evaluated by Patrick Duffy 20 Oct 2011
69. Schwenk RJ, Richie TL: Protective immunity to pre-erythrocytic
stage malaria. Trends Parasitol 2011, 27:306-14.
Page 9 of 9
(page number not for citation purposes)
F1000 Biology Reports 2011, 3:24 http://f1000.com/reports/b/3/24